ℹ️
🇬🇧
Search
Search for publications relevant for "MSBase"
MSBase
Publication
Class
Person
Publication
Programmes
publication
Nationwide Registry of Multiple Sclerosis ReMuS - The Importance of Data Collection from Real Clinical Practice
2017 |
First Faculty of Medicine
publication
REMUS-Czech national registry of patients with multiple sclerosis
2016 |
First Faculty of Medicine
publication
Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry
2021 |
First Faculty of Medicine
publication
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
2022 |
First Faculty of Medicine
publication
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry
2023 |
First Faculty of Medicine
publication
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
2023 |
First Faculty of Medicine
publication
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
2016 |
First Faculty of Medicine
publication
Defining secondary progressive multiple sclerosis
2016 |
First Faculty of Medicine
publication
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
2017 |
First Faculty of Medicine
publication
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS
2022 |
First Faculty of Medicine
publication
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
2018 |
First Faculty of Medicine
publication
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
2015 |
First Faculty of Medicine
publication
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis
2015 |
First Faculty of Medicine
publication
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder
2020 |
First Faculty of Medicine
publication
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
2020 |
First Faculty of Medicine
publication
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
2017 |
First Faculty of Medicine
publication
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
2021 |
First Faculty of Medicine
publication
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers
2023 |
First Faculty of Medicine
publication
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
2020 |
First Faculty of Medicine
publication
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
2022 |
First Faculty of Medicine
publication
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
2024 |
First Faculty of Medicine
publication
BREMSO: a simple score to predict early the natural course of multiple sclerosis
2015 |
First Faculty of Medicine
publication
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
2021 |
First Faculty of Medicine
publication
Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis
2020 |
First Faculty of Medicine
publication
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod
2018 |
First Faculty of Medicine
publication
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies
2021 |
First Faculty of Medicine
publication
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
2019 |
First Faculty of Medicine
publication
Contribution of different relapse phenotypes to disability in multiple sclerosis
2017 |
First Faculty of Medicine
publication
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis
2018 |
First Faculty of Medicine
publication
Multiple Sclerosis Relapses Following Cessation of Fingolimod
2022 |
First Faculty of Medicine